Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIR-5818 Alone and With Pembrolizumab in Advanced HER2-Expressing Cancers
NCT05356741Phase 2Recruiting
- Sponsor
- Vir Biotechnology
- Start
- Apr 2022
- Primary completion
- Apr 2028
- Countries
- 5
01
Overview
Phase 2, open-label trial of VIR-5818 in Human epidermal growth factor receptor 2 positive cancer (4 arms), sponsored by Vir Biotechnology. Primary endpoints: Incidence of dose-limiting toxicity at 42 days, Number of participants with treatment-emergent adverse events and serious adverse events at 55 months and 2 more. Started Apr 2022; status: recruiting.
02
Drugs
VIR-5818
03
Conditions
Human epidermal growth factor receptor 2 positive cancer
Beyond the preview
Go deeper on NCT05356741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05356741.